Proxalutamide (GT0918)

Catalog No.S9898 Batch:S989801

Technical Data

Formula

C₂₄H₁₉F₄N₅O₂S

Molecular Weight

517.50

CAS No.

1398046-21-3

Solubility (25°C)*

In vitro

DMSO

100 mg/mL (193.23 mM)

Ethanol

25 mg/mL (48.3 mM)

Water

Insoluble

In vivo (Add solvents to the product individually and in order)

Clear solution	5% DMSO 1 95% Corn oil	0.83mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 16.6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O	5.0mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Proxalutamide (GT0918) is a second-generation androgen receptor antagonist that binds to the ligand-binding domain of AR with an IC50 of 32 nM in the AR competive binding assays.

Targets

Androgen Receptor ^[1]
(in the AR competive binding assay)

32 nM

In vitro

Proxalutamide, a novel 2nd generation AR antagonist, binds to the ligand- binding domain of AR, with an IC50 of 32 nM in the AR competitive binding assays. Proxalutamide can block AR transcriptional activity, reduce AR protein levels, and obviously inhibit PCa growth in vitro. ^[1]

In vivo

The elimination half-life of proxalutamide in rats is approximately 2 h regardless of whether it is administered by the intragastric or the intravenous route. The maximum plasma concentration of proxalutamide can reach 2 μg/mL or higher, and the oral absolute bioavailability is approximately 80%. ^[2]

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines LNCaP cells Concentrations 0.32, 0.16, 0.8, 4, 20 mM Incubation Time 7 days Method LNCaP cells are seeded at a density of 2×10³ cells/ well in 96-well plates and incubated overnight for attachment. LNCaP cells are treated with Proxalutamide (0.32, 0.16, 0.8, 4 and 20 mM) for 7 d. After 20 ml of MTT solution (5 mg/ml) is added and incubated for 4 h at 37 C, the medium is removed. Then 150 ml of dimethyl sulfoxide (DMSO) is added to each well to dissolve formazan crystals by constant shaking for 10 min. The plates are read at 540 nm on a microplate reader and a doseeresponse curve is used to assess IC50.
Animal Study:^{^[2]}	Animal Models Sprague–Dawley rats Dosages 20 mg/kg Administration o.g., i.v.

Cell Assay:^{^[1]}

Cell lines
LNCaP cells
Concentrations
0.32, 0.16, 0.8, 4, 20 mM
Incubation Time
7 days
Method
LNCaP cells are seeded at a density of 2×10³ cells/ well in 96-well plates and incubated overnight for attachment. LNCaP cells are treated with Proxalutamide (0.32, 0.16, 0.8, 4 and 20 mM) for 7 d. After 20 ml of MTT solution (5 mg/ml) is added and incubated for 4 h at 37 C, the medium is removed. Then 150 ml of dimethyl sulfoxide (DMSO) is added to each well to dissolve formazan crystals by constant shaking for 10 min. The plates are read at 540 nm on a microplate reader and a doseeresponse curve is used to assess IC50.

Animal Study:^{^[2]}

Animal Models
Sprague–Dawley rats
Dosages
20 mg/kg
Administration
o.g., i.v.

References

Selleck's Proxalutamide (GT0918) has been cited by 1 publication

Evidences of neurological injury caused by COVID-19 from glioma tissues and glioma organoids [ CNS Neurosci Ther, 2024, 30(6):e14822]	PubMed: 38923860

Evidences of neurological injury caused by COVID-19 from glioma tissues and glioma organoids [ CNS Neurosci Ther, 2024, 30(6):e14822]

PubMed: 38923860

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.